Search

Your search keyword '"Gao, Qinglei"' showing total 614 results

Search Constraints

Start Over You searched for: Author "Gao, Qinglei" Remove constraint Author: "Gao, Qinglei"
614 results on '"Gao, Qinglei"'

Search Results

1. Proteogenomic insights into early-onset endometrioid endometrial carcinoma: predictors for fertility-sparing therapy response

5. Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study

7. A ribosomal gene panel predicting a novel synthetic lethality in non-BRCAness tumors

12. Adjuvant chemotherapy versus adjuvant concurrent chemoradiotherapy after radical surgery for early-stage cervical cancer: a randomized, non-inferiority, multicenter trial

13. Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors

14. Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer

17. Prognostic significance of positive peritoneal cytology in endometrial carcinoma based on ESGO/ESTRO/ESP risk classification: A multicenter retrospective study

19. Biomarker-driven targeted therapy in patients with recurrent platinum-resistant epithelial ovarian cancer (BRIGHT): protocol for an open-label, multicenter, umbrella study

20. Deep learning-enabled pelvic ultrasound images for accurate diagnosis of ovarian cancer in China: a retrospective, multicentre, diagnostic study

25. Semaphorin 4C accelerates disease progression and enables disease detection in breast cancer

33. Hyperbranched poly(β-amino ester) based polyplex nanopaticles for delivery of CRISPR/Cas9 system and treatment of HPV infection associated cervical cancer

42. Abstract CT079: Efficacy and safety of sintilimab (anti-PD-1 mAb) for advanced cervical cancer: Results from a Phase II trial

43. Supplementary Figure legends from Bepotastine Sensitizes Ovarian Cancer to PARP Inhibitors through Suppressing NF-κB–Triggered SASP in Cancer-Associated Fibroblasts

44. Figure S3 from Bepotastine Sensitizes Ovarian Cancer to PARP Inhibitors through Suppressing NF-κB–Triggered SASP in Cancer-Associated Fibroblasts

45. Table S1-S6 from Bepotastine Sensitizes Ovarian Cancer to PARP Inhibitors through Suppressing NF-κB–Triggered SASP in Cancer-Associated Fibroblasts

46. Data from Bepotastine Sensitizes Ovarian Cancer to PARP Inhibitors through Suppressing NF-κB–Triggered SASP in Cancer-Associated Fibroblasts

Catalog

Books, media, physical & digital resources